Designing the next generation of gene therapy treatments

GFP expression in the retinal vasculature The Ocular Gene Therapy Laboratory (OGTL) founded by Daniel M. Lipinski, DPhil, is dedicated to the development of novel therapies to prevent human blindness. Occupying >1,000 sq.ft. of research space within the Medical College of Wisconsin Eye Institute, OGTL provides the expertise and infrastructure to design the next generation of gene therapy treatments aimed at preventing retinal cell death or dysfunction.
OGTL News
Scientific Reports
August 06, 2018

Publication – OGTL research published in Scientific Reports

In an article published today, Chris Reid PhD, a recent graduate from the Lipinski Laboratory, describes the design of an inducible recombinant adeno-associated virus (rAAV)-based gene therapy treatment to prevent choroidal neovascularization (CNV) in age-related macular degeneration (AMD).
+Read More

 
Robert A. Brandt Macular Degeneration Fund
June 12, 2018

Congratulations – Dwani Patel receives Vision Research Trainee Grant.

The McPherson Eye Research Institute announced today that Dwani Patel, a second year PhD student in the OGTL, has been awarded one of only two Vision Research Trainee Grants for 2018.
+Read More

 
Robert A. Brandt Macular Degeneration Fund
June 01, 2018

Donation – Robert A. Brandt Macular Degeneration Fund.

The OGTL recently received a generous philanthropic donation of $75,000 from the Robert A. Brandt Macular Degeneration Fund.
+Read More

 
Key Publications

Reid CA, Nettesheim, E.R., Connor, T.B., Lipinski DM.  Development of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD   Sci Rep   8(1):11763 (2018).

 
 
 

Reid CA, Ertel KJ, Lipinski DM.   Improvement of Photoreceptor Targeting via Intravitreal Delivery in Mouse and Human Retina Using Combinatory rAAV2 Capsid Mutant Vectors.   Invest Ophthalmol Vis Sci.   2017 12 01;58(14):6429-6439.

 
 
 

Lipinski DM, Barnard AR, Singh MS, Martin C, Lee EJ, Davies WIL, MacLaren RE.   CNTF Gene Therapy Confers Lifelong Neuroprotection in a Mouse Model of Human Retinitis Pigmentosa.   Mol Ther.   2015 Aug;23(8):1308-1319.

 
 
 

Singh MS, Charbel Issa P, Butler R, Martin C, Lipinski DM, Sekaran S, Barnard AR, MacLaren RE.   Reversal of end-stage retinal degeneration and restoration of visual function by photoreceptor transplantation.   Proc Natl Acad Sci U S A.   2013 Jan 15;110(3):1101-6.

 

Histology - retinal layers

Upcoming Events
September 03-07, 2018 XVIIIth International Symposium on Retinal Degeneration
Killarney, Ireland
September 5, 2018

September Ophthalmology Grand Rounds: "Learning From Our (My) Mistakes "
George Bartley, MD
Louis J. and Evelyn Krueger Professor of Ophthalmology
Mayo Clinic
Faculty Host: Greg Griepentrog, MD

September 28-29, 2018 41st Annual Midwest Glaucoma Symposium and the Medical College of Wisconsin Eye Institute Annual Symposium 2018
Intercontinental Hotels - Milwaukee
Milwaukee, Wisconsin, 53202

Medical College of Wisconsin Eye Institute
925 North 87th Street
Milwaukee, WI 53226
414-955-2062
Fax: 414-955-6690

Email OGT
© 2018 Medical College of Wisconsin
top